Firms

LifeRock Ventures

LifeRock Ventures is a life-sciences investment firm backing therapeutic innovation, including gene and cell therapies and precision medicines. Its public website also describes investments in diagnostics, medical devices, digital health, healthcare services and applications of life-sciences technology beyond healthcare. Its verified neuroscience investment is Cerevance, a company developing precision therapies for central nervous system diseases using the NETSseq human brain transcriptomics discovery platform. Cerevance explicitly named LifeRock as a new participant in its USD 47 million Series B-1 extension announced on 25 April 2024; the round total is not LifeRock’s individual investment. The website identifies the brand as LifeRock Ventures, Inc. in its copyright footer. No verified named management roster, legal fund vehicles, fund-close sizes or individual investment amounts are published in the primary sources reviewed. The separate LLC trademark applicant has not been established as the same contracting entity, and no speculative family-office, founding-year or headquarters claims are asserted.

Founded: —
Type: Venture capital